DRAXIMAGE® DTPA

Lung ventilation*
DRAXIMAGE® DTPA

The radiopharmaceutical diethylenetriamine pentacetic acid (DTPA) is used to assess pulmonary ventilation function in association with macroaggregated albumin (MAA) to perform a ventilation/perfusion (V/Q) scan. Once deposited in the lungs, the 99mTc-DTPA aerosol particles remain in place for sufficient time to allow nuclear technologists to image multiple projections of the lungs in either SPECT or planar modes.

*DRAXIMAGE DTPA is indicated for lung ventilation in Canada only.

Brain imaging

The blood-brain barrier (BBB) refers to the anatomic and physiologic membrane between circulating blood and the brain preventing certain damaging substances from reaching brain tissue and cerebrospinal fluid. This barrier permits nutrients essential to brain tissue to readily cross the barrier while toxic and unwanted substances are restricted from passage. DRAXIMAGE® DTPA, although non-toxic, is a non-lipophilic agent that cannot penetrate the blood-brain barrier, unless there is a breakdown in the BBB as a result of disease.

Renal imaging

Complemented by other imaging modalities, radionuclide imaging has emerged as an important diagnostic tool in nephrology, urology, and renal transplantation. This functional information can be correlated to anatomical information from these complementary imaging studies or simultaneous hybrid imaging (eg, SPECT/CT).

Renal imaging and functional studies are recognized, well accepted, and proven as reliable means to evaluate the structure, function and physiology of the urinary tract as well as to determine the total and differential performance of the kidneys. This can be accomplished without danger of allergic reactions that are more common with iodinated X-ray contrast agents, unpleasant side effects, or excessive radiation dose to the organs involved.

Product Overview

Product Name

Kit for the Preparation of Technetium Tc 99m Pentetate Injection

Indications

  • May be used to perform kidney imaging and brain imaging, to assess renal perfusion and to estimate glomerular function rate (GFR).
  • When administered by inhalation following nebulization to a radio-aerosol, may be used to perform lung ventilation studies as an aid in the assessment of pulmonary embolic or obstructive disease.

Description

Each kit consists of reaction vials which contain the sterile, non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Pentetate Injection for diagnostic use by intravenous injection or for inhalation after the nebulization to radio-aerosol. Available in kits containing 10 reaction vials.

Note

  • Once reconstituted with Tc-99m sodium pertechnetate, DRAXIMAGE DTPA is stable for 12 hours with no time limitation for GFR determination in that time range.
  • The instructions accompanying the aerosol delivery system must be followed in order to ensure proper delivery of the radio-aerosol to the lungs.

Product Insert

Click to view Product Insert

MSDS

Click to view MSDS

DISCLAIMER:

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. For full Prescribing Information including indications, contraindications, warnings, precautions and adverse events, please see the appropriate product labeling.